written on 11.03.2014

Pfizer looks to maintain innovation lead in Japan


The target, which includes new indications and line extensions for existing products as well as new molecular entities (NMEs), follows a total of 11 launches, including six NMEs, by the subsidiary in the fiscal year ended 30 November.

Latest Reports